Print
Email
Print Edition Stories
Life sciences equipment supplier Thermo Fisher Scientific Inc. today announced that it has signed a license agreement with Alere Inc. to add its BRAHMS biomarker assays to Alere’s point-of-care Triage platform.
Waltham-based Thermo Fisher said that the biomarkers that will be available on the Triage system include the BRAHMS Procalcitonin (PCT) test for early detection of sepsis in critically ill patients. Severe sepsis is a life-threatening blood disease that affects 750,000 hospital patients in the U.S. each year, according to Thermo Fisher. Alere will also utilize BRAHMS Copeptin, MR-proADM and MR-proANP, which are novel biomarkers used to diagnose patients who experience symptoms such as chest pains or shortness of breath and seek treatment in a hospital emergency room.
Earlier this week, Thermo Fisher said it had purchased Ohio company TREK Diagnostic Systems for an undisclosed amount from its parent, Chelmsford’s Magellan Bioscience Inc.
Healthcare management company Alere was formerly Inverness Medical Innovations. Earlier this month, the company announced that it closed a $2 billion credit line and then made a $369 million bid for Scottish company Axis-Shield Plc, which rejected the offer, according to published reports.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
